Modulation of the estrogen-regulated proteins cathepsin D and pS2 by opioid agonists in hormone-sensitive breast cancer cell lines (MCF7 and T47D): Evidence for an interaction between the two systems

Journal of Cellular Biochemistry

Volumn 71, Issue 3, 1998, Pages 416-428

  Panagiotou, Simone ^a   Hatzoglou, Anastassia ^b   Calvo, Fabien ^c   Martin, Pierre Marie ^a   Castanas, Elias ^b  

^a INSERM   (France)

^b UNIVERSITY OF CRETE   (Greece)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

Cancer; Cathepsin D; Estrogen; Opioids; PS2

Indexed keywords

CATHEPSIN D; ESTROGEN; ETHYLKETAZOCINE; PROTEIN PS2;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; DRUG EFFECT; GROWTH INHIBITION; HORMONAL REGULATION; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION; SIGNAL TRANSDUCTION;

EID: 0032402977     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(19981201)71:3<416::AID-JCB10>3.0.CO;2-Y     Document Type: Article

References (55)

1. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS (1986): Phenol red in tissue culture media is a weak estrogen: Implications concerning the study of estrogen responsive cells in culture. Proc Natl Acad Sci U S A 83:2496-2500.
2. Bolufer P, Torregrosa MD, Gomez L, Munarriz B, Lopez JA, Asins E, Espinoza S, Vera F, Vazquez C, Guillem V (1996): Specific oncological contribution of cathepsin D and pS2 in human breast cancer: Their relationship with TNM status, estradiol receptors, epidermal growth factor receptor and neu amplification. Clin Chim Acta 247:89-103.
3. Cappelletti V, Fioravanti L, Miodini P, Di Fronzo G (1996): Modulation of cathepsin-D and pS2 protein levels in human breast cancer cell lines. Tumour Biol 17:290-298.
4. Castanas E, Bourhim N, Giraud P, Boudouresque F, Cantau P, Oliver C (1985a): Interaction of opiates with opioid binding sites in the bovine adrenal medulla: I. Interaction with delta and mu sites. J Neurochem 45:677-687.
5. Castanas E, Bourhim N, Giraud P, Boudouresque F, Cantau P, Oliver C (1985b): Interaction of opiates with opioid binding sites in the bovine adrenal medulla: II. Interaction with kappa sites. J Neurochem 45:688-699.
6. Confort C, Rochefort H, Vignon F (1995): Insulin-like growth factors (IGFs) stimulate the release of alpha 1-antichymotrypsin and soluble IGF-II/mannose 6-phosphate receptor from MCF7 breast cancer cells. Endocrinology 136:3759-3766.
7. Couissi D, Dubois V, Remacle C, Schonne E, Trouet A (1997): Western immunoblotting and enzymatic activity analysis of cathepsin D in human breast cancer cell lines of different invasive potential. Regulation by 17beta-estradiol, tamoxifen and ICI 182,780. Clin Exp Metastasis 15:349-360.
8. De Leon DD, Terry C, Asmerom Y, Nissley P (1996): Insulin-like growth factor II modulates the routing of cathepsin D in MCF-7 breast cancer cells. Endocrinology 137:1851-1859.
9. el-Tanani MK, Green CD (1996a): Insulin/IGF-1 modulation of the expression of two estrogen-induced genes in MCF-7 cells. Mol Cell Endocrinol 121:29-35.
10. el-Tanani MK, Green CD (1996b): Interaction between estradiol and cAMP in the regulation of specific gene expression. Mol Cell Endocrinol 124:71-77.
11. Ferrandina G, Scambia G, Bardelli F, Benedetti Panici P, Mancuso S, Messori A (1997): Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: A meta-analysis. Br J Cancer 76:661-666.
12. Garcia M, Platet N, Liaudet E, Laurent V, Derocq D, Brouillet JP, Rochefort H (1996): Biological and clinical significance of cathepsin D in breast cancer metastasis. Stem Cells 14:642-650.
13. Gkonos PJ, Krongrad A, Roos BA (1995): Neuroendocrine peptides in the prostate. Urol Res 23:81-87.
14. Glikman P, Rogozinski A, Mosto J, Pollina A, Garbovesky C, Levy C (1997): Relationship between cathepsin-D and other prognostic factors in human breast cancer. Tumori 83:685-688.
15. Gohring UJ, Scharl A, Thelen U, Ahr A, Crombach G (1996): Comparative prognostic value of cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma. Anticancer Res 16:1011-1018.
16. Hatzoglou A, Ouafik LH, Bakogeorgou E, Thermos K, Castanas E (1995): Morphine cross-reacts with somatostatin receptor SSTR2 in the T47D human breast cancer cell line, and decreases cell proliferation. Cancer Res 65:5632-5636.
17. Hatzoglou A, Bakogeorgou E, Hatzoglou C, Martin P-M, Castanas E (1996a): Antiproliferative and receptor binding properties of α-and β-casomorphin peptides, in the T47D human breast cancer cell line. Eur J Pharmacol 310:217-223.
18. Hatzoglou A, Bakogeorgou E, Castanas E (1996b): The antiproliferative effect of opioid agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors. Eur J Pharmacol 296:199-207.
19. Herman ME, Katzenellenbogen BS (1996): Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen. J Steroid Biochem Mol Biol 59:121-134.
20. Horiguchi J, Iino Y, Takei H (1996): Expression of pS2 estrogen-inducible protein in primary breast cancer. Oncology 53:12-15.
21. Hytrek SD, Smith JP, McGarrity TJ, McLaughlin PJ, Lang CM, Zagon IS (1996): Identification and characterization of zeta-opioid receptor in human colon cancer. Am J Physiol 271:R115-121.
22. Isayama T, McLaughlin PJ, Zagon IS (1991): Endogenous opioids regulate cell proliferation in the retina of developing rat. Brain Res 544:79-85.
23. Joensuu H, Toikkanen S, Isola J (1995): Stromal cell cathepsin D expression and long-term survival in breast cancer. Br J Cancer 71:155-159.
24. Kampa M, Bakogeorgou E, Hatzoglou A, Damianaki A, Martin P-M, Castanas E (1997): Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3, and DU145) through a partial interaction with opioid receptors. Eur. J. Pharmacol. 335:255-266.
25. Khan SA, Gonchoroff NJ, Miller LE (1997): Expression of pS2, c-erbB-2, and cathepsin D during the menstrual cycle in human breast cancers. Ann Surg Oncol 4:462-469.
26. Levin RJ, Wu Y, McLaughlin PJ, Zagon IS (1997): Expression of the opioid growth factor, [Met5]-enkephalin, and the zeta opioid receptor in head and neck squamous cell carcinoma. Laryngoscope 107:335-339.
27. Lowry OH, Rosenbrough N, Farr A, Randall R (1951): Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
28. Maneckjee R, Minna JD (1990): Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci U S A 87:3294-3298.
29. Maneckjee R, Biswas R, Vonderhaar BK (1990): Binding of opioids to human MCF-7 breast cancer cells, and their effects on growth. Cancer Res 50:2234-2238.
30. Martin V, Ribieras S, Song-Wang XG, Lasne Y, Frappart L, Rio MC, Dante R (1997): Involvement of DNA methylation in the control of the expression of an estrogen-induced breast-cancer-associated protein (pS2) in human breast cancers. J Cell Biochem 65:95-106.
31. May FE, Westley BR (1997): Expression of human intestinal trefoil factor in malignant cells and its regulation by oestrogen in breast cancer cells. J Pathol 182:404-413.
32. Nadji M, Fresno M, Nassiri M, Conner G, Herrero A, Morales AR (1996): Cathepsin D in host stromal cells, but not in tumor cells, is associated with aggressive behavior in node-negative breast cancer. Hum Pathol 27:890-895.
33. Nichols PH, Ibrahim NB, Padfield CJ, Cawthorn SJ (1995): Correlation of pS2 expression of involved lymph nodes in relation to primary breast carcinoma. Eur J Surg Oncol 21:151-154.
34. Noordzij MA, van Steenbrugge GJ, van der Kwast T, Schroder FH (1995): Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate. Urol Res 22:333-341.
35. Panagiotou S, Martin P-M, Castanas E (1997): Opioid agonists decrease the concentration of steroid receptors in hormone-sensitive breast cancer cell lines. In "2emes Journees of the IFR Jean Roche." Marseille, France: Abstract C4.
36. Papakonstanti EA, Bakogeorgou E, Castanas E, Emmanuel DS, Harting R, Stournaras C (1998): Early alterations of actin cytoskeleton by opioids. J Cell Biochem 70:60-69.
37. Pelizzola D, Gion M, Paradiso A, Dittadi R, Correale M, Mione R, Piffanelli A (1996): Cathepsin D versus other prognostic factors in breast cancer. Results and controversies of a multicenter study on 2575 cases. Int J Biol Markers 11:139-147.
38. Racca S, Conti G, Pietribiasi F, Stramignoni D, Tampellini M, Valetto MR, Ghezzo F, Di Carlo F (1995): Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer. Int J Biol Markers 10:87-93.
39. Rajah TT, Dunn ST, Pento JT (1996): The influence of antiestrogens on pS2 and cathepsin D mRNA induction in MCF-7 breast cancer cells. Anticancer Res 16:837-842.
40. Ravdin PM, de Moor CA, Hilsenbeck SG, Samoszuk MK, Vendely PM, Clark GM (1997): Lack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients. Cancer Lett 116:177-183.
41. Razumovic JJ, Stojkovic RR, Petrovecki M, Gamulin S (1997): Correlation of two methods for determination of cathepsin D in breast carcinoma (immunohistochemistry and ELISA in cytosol). Breast Cancer Res Treat 43:117-122.
42. Rochefort H (1995): Oestrogen-and anti-oestrogen-regulated genes in human breast cancer. Ciba Found Symp 191:254-265; discussion 265-268.
43. Schwartz MK (1995): Tissue cathepsins as tumor markers. Clin Chim Acta 237:67-78.
44. Scopsi L, Balslev E, Brunner N, Skovgaart-Poulsen H, Andersen J, Rank F, Larson L-I (1989): Immunoreactive opioid peptides in human breast cancer. Am J Pathol 134:473-479.
45. Soubeyran I, Quenel N, Coindre JM, Bonichon F, Durand M, Wafflart J, Mauriac L (1996): pS2 protein: A marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Br J Cancer 74:1120-1125.
46. Spyratos F, Martin PM, Hacene K, Romain S, Andrieu C, Ferrero-Pous M, Deytieux S, Le Doussal V, Tubiana-Hulin M, Brunet M (1992): Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84:1266-1272.
47. Zagon IS, McLaughlin PJ (1987): Endogenous opioid systems regulate cell proliferation in the developing rat brain. Brain Res 412:68-72.
48. Zagon IS, McLaughlin PJ (1989): Endogenous opioid systems regulate growth of neural tumor cells in culture. Brain Res 490:14-25.
49. Zagon IS, McLaughlin PJ, Goodman SR, Rhodes RE (1987a): Opioid receptors and endogenous opioids in diverse human and animal cancers. J Natl Cancer Inst 79:1059-1065.
50. Zagon IS, McLaughlin PJ, Goodman SR, Rhodes RE (1987b): Opioid receptors and endogenous opioids in diverse human and animal cancers. J Natl Cancer Inst 79:1059-1065.
51. Zagon IS, Goodman SR, McLaughlin PJ (1989): Characterization of zeta (zeta): A new opioid receptor involved in growth. Brain Res 482:297-305.
52. Zagon IS, Goodman SR, McLaughlin PJ (1990): Demonstration and characterization of zeta (zeta), a growth-related opioid receptor, in a neuroblastoma cell line. Brain Res 511:181-186.
53. Zagon IS, Hytrek SD, Lang CM, Smith JP, McGarrity TJ, Wu Y, McLaughlin PJ (1996a): Opioid growth factor ([Met5]enkephalin) prevents the incidence and retards the growth of human colon cancer. Am J Physiol 271: R780-R786.
54. Zagon IS, Hytrek SD, McLaughlin PJ (1996b): Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture. Am J Physiol 271:R511-R518.
55. Zagon IS, Wu Y, McLaughlin PJ (1997): Opioid growth factor is present in human and mouse gastrointestinal tract and inhibits DNA synthesis. Am J Physiol 272: R1094-R1104.